Target Audience
This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract. Other healthcare professionals may find this program beneficial. No specific knowledge other than a basic understanding of cancer and the digestive system is necessary to participate in this course.

Educational Objectives:
After successfully completing this continuing medical education program participants should be able to:

• Identify current controversies in the management of patients with gastric or esophageal cancers
• Discuss current and new treatment options for patients with gastric or esophageal cancers
• Comment on available treatment options for rare gastrointestinal stromal tumors
• Discuss management of patients with cancer of the liver
• Understand adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
• Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
• Determine the most appropriate surgical procedures for early stage colon cancer
• Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
• Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results
• Identify treatment strategies for rectal cancer

Unapproved and Investigational Uses of Drugs and Devices
This webcast may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex®, Inc. or the meeting supporters.

Program Organizer
Imedex^®, Inc.
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751 7334

Disclosure of Financial Interests
As an accredited provider of Continuing Medical Education, Imedex, Inc. is required to ask speakers to disclose any real or apparent conflict of interest they may have as related to the contents of their presentation(s). The existence of commercial or financial interests of speakers related to the subject matter of their presentation(s) should not be construed as implying bias or decreasing the value of their presentation(s). However, disclosure should help participants form their own judgments.

All speakers were independently selected by the organizing committee. Those speakers who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.

1=grant/research support 2=consultant 3=speaker's bureau 4=stock shareholder 5=other support

The following speakers have reported an affiliation with non-supporting companies of this Congress:

• Jervoise Andreyev, MA, PhD, FRCP - Nutricia¹
• Nadir Arber, MD - GI View²
• Martyn Caplin, MD - Ipsen¹, Novartis¹
• Bernard Levin, MD - Enterix²
• Howard L. McLeod, MD - National Institutes of Health¹, Orion Genomics², Precision Therapeutics², Prometheus Laboratories²,
  Third Wave Technologies², Veridex LLC²
• Neil J. Meropol, MD - Bristol-Myers Squibb², Genentech^1,2, GSK²
• Bruce D. Minsky, MD - Bristol-Myers Squibb^1,2,3, Genentech^1,2,3
• Malcolm J. Moore, MD - Genentech^2,3, OSI^1,2
• Mace L. Rothenberg, MD - ImClone Systems, Inc.¹
• Margaret A. Tempero, MD - Human Genome Science, Inc.², ImClone Systems, Inc.², Oxigene², Raven Biothechnologies²
• Melanie B. Thomas, MD - Genentech¹
• John Zalcberg, MD - Novartis^1,2

The following speakers have reported an affiliation with the supporters of this Congress:

• Nadir Arber, MD -Pfizer^1,2
• David Cunningham, MD, FRCP - Roche^1,2,5
• Volker Heinemann, MD, PhD - Eli Lilly and Company²
• Bernard Levin, MD - Pfizer¹
• Christophe Louvet, MD - Pfizer¹, sanofi-aventis¹
• Howard L. McLeod, MD - Pfizer²
• Neil J. Meropol, MD - Amgen², Pfizer^1,2
• Bruce D. Minsky, MD - Roche^1,2, sanofi-aventis^1,2
• Malcolm J. Moore, MD - Roche^1,3
• Mace L. Rothenberg, MD - Pfizer¹, Roche^1,2, sanofi-aventis¹
• Philipe Rougier, MD - Merck², Pfizer², sanofi-aventis²
• Hans-Joachim Schmoll, MD, PhD - Roche1, sanofi-aventis^1,2

The following speakers do not report any affiliation:

• Pierre Bedossa, MD
• Jordi Bruix, MD
• Stefano Cascinu, MD
• Andre D'Hoore, MD
• Eduardo Dнaz-Rubio, MD
• Michel Ducreux, MD, PhD
• Manuel Esteller, MD
• Jean Faivre, MD
• Roldano Fossati, MD
• Jean-Pierre Gerard, MD
• Robert Glynne-Jones, MD, FRCP
• Thomas Gruenberger, MD
• Stanley R. Hamilton, MD
• Karin Haustermans, MD, PhD
• Patrick Johnston, MD, PhD
• David J. Kerr, MD, FRCP, FMedSc
• Florian Lordick, MD
• Lars Lundell, MD, PhD
• Henry T. Lynch, MD
• John S. Macdonald, MD
• Masatoshi Makuuchi, MD, PhD
• Bernard Nordlinger, MD
• Lars Pеhlman, MD
• Nicholas A. Pavlidis, MD, FACS
• Vicenzo Valentini, MD
• Cornelis J.H. van de Velde, MD, PhD
• Emanuele Zucca, MD

The following speakers did not return a disclosure form:

• Rene Adam, MD
• Gina Brown, MD
• Alfredo Carrato, MD, PhD
• Serena Di Cosimo, MD
• Aimery de Gramont, MD
• Mario Dicato, MD
• John W.L. Fielding, MD
• Jola Gore-Booth
• Daniel G. Haller, MD
• Paulo M. Hoff, MD, FACP
• Roberto Labianca, MD
• M. Teresa Macarulla, MD
• Erika Martinelli, MD
• Hеkan Mellstedt, MD, PhD
• Sergio Pedrazzoli, MD, FACS
• Francesco Pignatti, MD
• Maria Simona Pino, MD
• F. Javier Ramos, MD
• Arnaud D. Roth, MD
• Philippe Ruszniewski, MD
• Josep Tabernero, MD
• Eric Van Cutsem, MD, PhD
• Bertram Wiedenmann, MD

Imedex^®, Inc. is an independent provider of Continuing Medical Education. Imedex, Inc. has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.

© 2006 Imedex^®, Inc. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

Systems Requirements
• Pentium 500 processor or greater
• Windows 98/NT/2000/XP or Mac OS 9/X
• Microsoft Internet Explorer 5.5 or later
• Windows Media Player 9.0 or later
• 128 MB of RAM
• Monitor settings: High color at 800 x 600 pixels
• Sound card and speakers
• Abstracts require Adobe Acrobat Reader